avapritinib   Click here for help

GtoPdb Ligand ID: 10368

Synonyms: Ayvakit® | Ayvakyt® | BLU-285 | BLU285
Approved drug Immunopharmacology Ligand
avapritinib is an approved drug (FDA & EMA (2020))
Compound class: Synthetic organic
Comment: Avapritinib (BLU-285) was developed by Blueprint Medicines as an oral precision therapy to selectively and potently inhibit KIT and PDGFRA mutant kinases [3]. It is a Type I kinase inhibitor that binds the active kinase conformation. Avapritinib binds to the 'switch pocket' of KIT, a domain that regulates the enzyme's catalytic conformation. Compounds that act in this way are often referred to as switch control inhibitors [1]. Another such switch control inhibitor is ripretinib.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 106.29
Molecular weight 498.24
XLogP 4.21
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Fc1ccc(cc1)C(c1cnc(nc1)N1CCN(CC1)c1ncnn2c1cc(c2)c1cnn(c1)C)(N)C
Isomeric SMILES Fc1ccc(cc1)[C@@](c1cnc(nc1)N1CCN(CC1)c1ncnn2c1cc(c2)c1cnn(c1)C)(N)C
InChI InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1
Immunopharmacology Comments
A constitutively active mutant KIT (typically D816V) is present in 90-95% of cases of systemic mastocytosis and drives disease pathogenesis. The multi-kinase inhibitor midostaurin is currently the only approved treatment for advanced/aggressive systemic mastocytosis [4]. Avapritinib was designed to directly target the active conformation of KIT, so as to potently and selectively inhibit KITD816V and other activation loop mutants [3] that confer resistance to early generation kinase inhibitors such as imatinib.